Kanglong Chemical (03759) overseas subsidiary plans to make a capital contribution of 30 million US dollars to participate in an overseas equity investment fund.

Smart Finance App News, Kanglong Huacheng (03759) announced that in order to fully utilize the professional investment institutions' abilities in the biopharmaceutical industry for investment and judgment, the company's wholly-owned subsidiary Pharmaron UK Limited (hereinafter referred to as "Kanglong UK") intends to subscribe for 30 million US dollars in capital as a limited partner with its own funds to participate in the investment in BLC Healthcare USD Fund I L.P. (hereinafter referred to as the "Fund" or "Partnership"). On May 30, 2025, Kanglong UK signed the "Amended and Restated Agreement of Exempted Limited Partnership of BLC Healthcare USD Fund I L.P." (hereinafter referred to as the "Partnership Agreement").